Evidence map›Paper›PMID 10854220›Full record

Trial reportThe American journal of pathology2000

Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection.

H Kuster, M Opravil, P Ott, E Schlaepfer, M Fischer, H F Günthard, R Lüthy, R Weber, R W Cone

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. T-Cell Signaling in HIV-1 Infection.The open virology journal · 2013
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  11. Article
  12. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2005
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

H KusterDepartment of Internal Medicine, University Hospital Zurich, Switzerland. herbert.kuster@dim.usz.ch
M Opravil
P Ott
E Schlaepfer
M Fischer
H F Günthard
R Lüthy
R Weber
R W Cone
University Hospital of Zurich · CHCarolina Ear, Nose and Throat Clinic · US

Funding

Wellcome Trust
6 · The paper itself

Abstract

We report detailed quantitative analysis of human immunodeficiency virus-1 (HIV-1) p24 and HIV-1 RNA in tonsil biopsies from 13 patients with early, asymptomatic HIV infection before and during combination antiretroviral therapy. Using fluorescent microscopy in conjunction with reverse transcriptase-polymerase chain reaction of frozen tissue sections, we show that plasma and tissue viral loads decreased by approximately 3 logs during the 1-year treatment period, with good correlation between the HIV-1 p24 and HIV-1 RNA response in tissue. The decrease of tissue viral load was delayed compared to plasma viral load, possibly explained by the observation that the amount of follicular dendritic cell-associated virus correlated best with the area under the curve of plasma HIV-1 RNA throughout the last 12 weeks. Before and during treatment, the relative proportions of HIV-1 on follicular dendritic cells and within mononuclear cells remained constant, suggesting similar decay characteristics in these two lymphoid tissue compartments. However, viral p24 or RNA remained almost always detectable in tissue despite full suppression of HIV-1 RNA in plasma, and increased even after short-term rebounds in plasma viral load. Thus, full and sustained suppression of viral replication was required to efficiently decrease viral load in lymphoid tissue, but complete abolition of residual viral replication was not achieved.

Indexed as

HIV-1Anti-HIV AgentsDrug Therapy, CombinationHIV Core Protein p24HIV InfectionsHumansLymphoid TissueRNA, MessengerRNA, ViralTissue DistributionTreatment OutcomeViral LoadAnti-HIV AgentsHIV Core Protein p24RNA, MessengerRNA, Viral

Identifiers

PMID10854220
PMCPMC1850084
OpenAlexW1973503572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.